Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ACU193 targets amyloid-beta oligomers and is a different approach to treating Alzheimer's disease than currently approved medications. ACU193 is designed to locate and bind to amyloid-beta oligomers – proteins that build up in the brain.
Lead Product(s): ACU193
Therapeutic Area: Neurology Product Name: ACU193
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Acumen Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2022